Clinical pharmacy tackling inequalities and access to health care
Important Dates And Deadlines

Symposium on-line registration open: 1 April, 2016
Abstract submission open: 1 May, 2016
Extended abstract submission deadline: 11 July, 2016
Early-bird registration deadline: 31 July, 2016
Notification to abstract submitters: 26 August 2016
Early-bird registration deadline for abstract presenters: 12 September 2016

https://www.facebook.com/escpweb/?fref=ts
SYMPOSIUM COMMITTEES

ESCP President
Markus Lampert (CH)

Symposium President
Frank Jørgensen (NO)

Scientific Committee
Frank Jørgensen (NO) – Chair
Bart van den Bemt (NL)
Olivier Bourdon (FR)
Beate Garcia (NO)
Stine Haustreis (NO)
Fikret Vehbi Izzettin (TR)
Carole Kaufmann (CH)
Reidun L.S. Kjome (NO)
Derek Stewart (GB)
Janne Kutscher Sund (NO)
Kirsten K. Viktil (NO)

Organizing Committee
Anne Gerd Granås (NO) - Chair
Liv Mathiesen (NO)
Anne-Lise Sagen Major (NO)
Kari Christiane Fougner Bjerknes (NO)
Daniela Scala (IT)
Edwin van Aalten (NL)

ESCP General Committee
Markus Lampert (CH), President
Olivier Bourdon (FR), Vice-President-Treasurer
Tobias Dreischulte (UK), Secretary
Fernando Fernandez-Llimos (PT)
Anne Gerd Granås (NO)
Daniela Scala (IT)
Stephane Steurbaut (BE)
Bart van den Bemt (NL)
The European Society of Clinical Pharmacy (ESCP) was founded in October 1979 during the 8th European Symposium on Clinical Pharmacy in Lyon, France. The objective of the Society is to develop and promote the rational and appropriate use of drugs and medical devices for the benefit of individuals and of society. Each year the Society organises an Annual Symposium, usually held in October. At this Symposium, papers in the field of pharmacotherapy, pharmacokinetics, clinical practice and various other subjects related to the aims of ESCP are presented.

Disclaimer
All the information on the scientific and social program, as outlined in this Preliminary Program, is subject to change in finalisation of the ESCP European Symposium Final Program.

Impressum
Graphic design and layout: white suitcase, Geneva http://www.white-suitcase.ch

Front page: View of the Oslo BarCode Buildings (2008–2014), masterplan designed by Dark Architects (NO), a-lab (NO) and MVRDV (NL).
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invitation from the Presidents</td>
<td>2</td>
</tr>
<tr>
<td><strong>Generalities</strong></td>
<td>3</td>
</tr>
<tr>
<td>Awards</td>
<td>4</td>
</tr>
<tr>
<td>Contribution from Participants</td>
<td>4/5</td>
</tr>
<tr>
<td>Financial support for ESCP Conference Attendees</td>
<td>6</td>
</tr>
<tr>
<td>Industry Sponsorship and Exhibition Opportunities</td>
<td>7</td>
</tr>
<tr>
<td>Practical Information</td>
<td>8</td>
</tr>
<tr>
<td>Symposium Registration</td>
<td>11</td>
</tr>
<tr>
<td>Accommodation</td>
<td>13</td>
</tr>
<tr>
<td>Oslo City Map</td>
<td>14</td>
</tr>
<tr>
<td>Special Programme Announcements</td>
<td>15</td>
</tr>
<tr>
<td>The Steve Hudson Lecture</td>
<td>15</td>
</tr>
<tr>
<td><strong>Scientific Programme</strong></td>
<td>16</td>
</tr>
<tr>
<td>Tuesday, October 4, 2016</td>
<td>16</td>
</tr>
<tr>
<td>Masterclass of Excellence in Pharmacy</td>
<td>17</td>
</tr>
<tr>
<td>Evening Opening Lecture</td>
<td>18</td>
</tr>
<tr>
<td>Wednesday, October 5, 2016</td>
<td>19</td>
</tr>
<tr>
<td>Thursday, October 6, 2016</td>
<td>23</td>
</tr>
<tr>
<td>Friday, October 7, 2016</td>
<td>29</td>
</tr>
<tr>
<td>Workshops</td>
<td>31</td>
</tr>
<tr>
<td>Programme at a Glance</td>
<td>24</td>
</tr>
</tbody>
</table>
Dear Colleagues

On behalf of the European Society of Clinical Pharmacy and the Norwegian Association of Hospital Pharmacists, we proudly invite you to participate in the 45th ESCP symposium in Oslo, Norway, on October 5th–7th 2016. For the second time, Norway is proud of hosting ESCP in Oslo.

The main theme is “Clinical pharmacy tackling inequalities and access to health care”. Clinical pharmacists are frequently asked to advice on appropriate therapies, from either pharmaceutical/medical or economic perspectives. It is ethically challenging to arrive at appropriate decisions, especially when the outcome is uncertain, the medicine expensive and the budget limited. The theme of our symposium reflects the increasingly widening gap between what is technologically possible to achieve with medicines, their increasing cost, and what is affordable to society and individual patients.

The last day of the symposium concerns long-term conditions in children and antimicrobial resistance, two major public health issues where appropriate use of medicines is vital to achieve good outcomes for patients and the society.

We hope the extensive symposium program will support you in providing good pharmaceutical care, give insight in innovative clinical pharmacy developments, and inspire you on how to tackle challenges of inequalities and access to health care. We invite you to discuss all these topics in Oslo, so we can make the best decisions according to patients' and society's needs.

Markus Lampert, President ESCP
Frank Jørgensen, President NSF
Symposium President
View of the Oslo Opera House (2008), designed by Snøhetta, a Norwegian-American architecture office.

Generalities

Awards .......................................................................................................................... 4
Contribution from Participants .................................................................................. 4/5
Financial Support for Symposium Attendees ......................................................... 6
Industry Sponsorship and Exhibition Opportunities .............................................. 7
Practical Information ............................................................................................... 8
Symposium Registration ......................................................................................... 11
Accommodation ...................................................................................................... 13
Oslo City Map .......................................................................................................... 14
Special Program Announcements .......................................................................... 15
The Steve Hudson Lecture ....................................................................................... 15
ESCP Poster Award and oral Communication Award 2016
The ESCP will present an award for the best poster and the best oral communication presented during the Symposium. Everyone is invited to submit abstracts for consideration. The award winners will be announced during the Closing Ceremony on Friday.

Criteria for Award winners
The jury will review the submitted abstracts according to the selection criteria for award winners. These criteria are applicable for both the ESCP Poster Award and Oral Communication Award. They are:
1. Originality and aim: valid innovative work is valued over more routine methods; new findings are valued over a confirmation of old findings, unless controversial. The aim of the work should be clear.
2. Design of a study or service: the study or service should be described in sufficient detail to allow understanding of its purpose and general structure; the objectives and methods should be clearly defined.
3. Results: results or accomplishments should be stated concisely and should relate to the original aim and objectives. Final results and accomplishments are rated more highly than interim reports.
4. Conclusions: conclusions should address the aim and objectives and should follow logically from the results; the utility of the data and their potential role in the management of patients should be emphasised.
5. Value to clinical pharmacy: a subject is of practical significance if it stimulates discussion among clinical pharmacists. The poster or oral communication can describe a novel approach or technique in practice or develop the role of the clinical pharmacist in the care of patients.

The deadline for submission of abstracts: 11 July 2016, midnight CET. Abstracts submitted after the deadline will not be accepted.

Submission
All participants of the symposium are invited to make submissions for adjudication by the Scientific committee of the symposium. The Committee will accept or reject the work on the basis of the structured abstract. All accepted submissions, except oral communications, will be presented in poster format. Acceptance or rejection will be sent to the authors on 26 August 2016. After acceptance, authors are entitled to register at the early-bird-fee for another 17 days: deadline 12 September 2015.
How to Submit an Abstract
Abstracts may only be submitted electronically via www.escpweb.org. Carefully fill in the online form, providing all requested information. The deadline for submission is the 11th July 2016, midnight CET. Abstracts submitted after the deadline will not be accepted.

Poster Presentation and Display
Posters related to different subjects within the scope of clinical pharmacy will be displayed at the symposium from 5 October, 10 am, to 7 October, 2 pm. Accepted submissions will be presented as posters. Selected submissions considered to have especially broad appeal may be assigned to a poster discussion forum or an oral communication. If an abstract has been accepted for presentation as an oral communication, authors are not required to present their work also as a poster. Authors will be asked to be present at their poster during the coffee breaks. The maximum size of the poster is 90 cm wide by 135 cm high. Adhesive material for poster presenters is provided by the organisers.

Poster Discussion Forums
This year the poster presentations shall are to be given in a “Pecha Kucha 20x20” format. The authors will also present posters in the poster area.

Pecha Kucha is a simple presentation format where you show 20 power-point images, each for 20 seconds. The images advance automatically and you talk along to the images. This leaves the presenter a total of 7 minutes to get the message across to the audience. The format, which keeps presentations concise and structured, should use less text and more images than usually seen in academic presentation. The idea is to really focus on the main message from your research and present them in an engaging way. There will be no time for discussions with questions and answer, however, in your Pecha Kucha presentation, you should engage the audience to get interested in your research. The will be able to come and talk to you in the poster exhibition area or catch up with you in the coffee breaks. The internet has numerous examples of how to make a Pecha Kucha presentation, here is a link to two examples: https://www.youtube.com/watch?v=tZU4OOnYv1A https://www.youtube.com/watch?v=32WEzmMzFhw.

Oral Communications
Oral communications consist of 15-minute presentations by the authors on the contents of their abstracts, including 5-minute discussions with questions and answers. Authors are not required
to present their work also as a poster. ESCP would like to assist in the education of clinical pharmacists in developing countries. A way of doing this is to make the ESCP Symposia more accessible for pharmacists from these countries. ESCP therefore offers financial support, consisting of free registration to the 45th ESCP European Symposium on Clinical Pharmacy. The pharmacist who requests financial assistance should live and work in a developing country. In Table 1 you will find a listing of countries not eligible, according to the World Bank list of economies July 2015.

An additional condition is that the applicant must be active in developing clinical pharmacy in his/her country. As this would be difficult to measure, ESCP requests that:

- The pharmacist has an abstract submitted and accepted for presentation at the symposium
- The pharmacist writes a short article on the symposium, which should be published in her/his national journal.

A copy of this publication should be sent to the ESCP International Office.

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andorra</td>
<td>Curaçao</td>
<td>Iceland</td>
<td>New Caledonia</td>
</tr>
<tr>
<td>Antigua &amp; Barbuda</td>
<td>Cyprus</td>
<td>Ireland</td>
<td>New Zealand</td>
</tr>
<tr>
<td>Aruba</td>
<td>Czech Republic</td>
<td>Isle of Man</td>
<td>Northern Mariana Islands</td>
</tr>
<tr>
<td>Australia</td>
<td>Denmark</td>
<td>Israel</td>
<td>Norway</td>
</tr>
<tr>
<td>Austria</td>
<td>Equatorial Guinea</td>
<td>Italy</td>
<td>Oman</td>
</tr>
<tr>
<td>Bahamas, The</td>
<td>Estonia</td>
<td>Japan</td>
<td>Poland</td>
</tr>
<tr>
<td>Bahrain</td>
<td>Faeroe Islands</td>
<td>Korea, Rep.</td>
<td>Portugal</td>
</tr>
<tr>
<td>Barbados</td>
<td>Finland</td>
<td>Kuwait</td>
<td>Puerto Rico</td>
</tr>
<tr>
<td>Belgium</td>
<td>France</td>
<td>Liechtenstein</td>
<td>Qatar</td>
</tr>
<tr>
<td>Bermuda</td>
<td>French Polynesia</td>
<td>Lithuania</td>
<td>San Marino</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>Germany</td>
<td>Luxembourg</td>
<td>Qatar</td>
</tr>
<tr>
<td>Canada</td>
<td>Greece</td>
<td>Macao SAR, China</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Cayman Islands</td>
<td>Greenland</td>
<td>Malta</td>
<td>San Marino</td>
</tr>
<tr>
<td>Channel Islands</td>
<td>Guam</td>
<td>Monaco</td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>Chile</td>
<td>Hong Kong SAR, China</td>
<td>Netherlands, The</td>
<td>Singapore</td>
</tr>
<tr>
<td>Croatia</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Countries not eligible, according to the World Bank list of economies July 2016
• The pharmacist is interviewed during the symposium and the interview will be edited for publication in the ESCP Newsletter.  

*In granting financial support, priority will be given to the following applicants:*
• ESCP Members, taking into account the duration of their membership
• Applicants whose abstracts have been accepted for presentation as oral communication or in the poster discussion forum during the symposium
• Applicants with the most experience in clinical pharmacy, which will be determined by the quality of abstract(s) submitted and the applicants’ Curriculum Vitae
• Applicants who have not previously received financial support from ESCP.

Should you wish to benefit from such support and be able to meet the criteria described above, we invite you to send your financial support request and Curriculum Vitae by e-mail to the ESCP International Office at: international.office@escpweb.org. The deadline to submit financial support applications is 10 September, 2016.

**

The sponsorship opportunities offer something for every budget and marketing strategy to raise your company’s profile with a combination of advertising, sponsorship and other promotional items. An exhibition will be organised in conjunction with the symposium. In addition, a wide range of additional promotional items ranging from inserts in delegates bags, to pens, adverts and more is also being offered. The symposium also offers the opportunity for your company to be directly involved and increase visibility and impact by organising a satellite symposium. Time slots for satellite symposia are available at lunch time.

Demonstrate your commitment to the rational and appropriate use of medicines by exhibiting or becoming a sponsor at the ESCP Symposium on Clinical Pharmacy.

**Contact for Exhibitors and Sponsors**
To reserve your space and participation today or to know more about promotional opportunities, please contact:

*Guillaume Dupuy*
*Exhibition Coordinator*
*Congress-Conference AS.*
*Frederik Stangs gate 14C*
*0272 Oslo, Norway*
*Phone: + 47 22 56 19 30*
*e-mail: guillaume@ccnorway.no*
CONGRESS-CONFERENCE AS has been selected by ESCP as the Official Symposium Organiser for the 2016 Symposium to process registrations, hotel reservations and excursions. All correspondence should be sent to the Symposium Secretariat at: escp2016@ccnorway.no, tel: + 47 22 56 19 30

Symposium Venue:
The historic Dragon Building at Scandic Holmenkollen Park Hotel, 350 m above the Oslo City Centre:
Scandic Holmenkollen Park Hotel
Kongeveien 26
0787 Oslo, Norway
http://www.holmenkollenparkhotel.no/en

How to get from Oslo Airport to Scandic Holmenkollen Park Hotel
https://www.google.com/maps/dir/Oslo+Airport,+Edvard+Munchs+veg,+Gardermoen,+Nor%CE%B1%CE%B3%A8ge/Scandic+Holmenkollen+Park,+Kongeveien+26,+0787+Oslo,+Nor%CE%B1%A8ge/@60.1772194,10.7391873,9z/data=!4m13!4m12!1m5!1m1s0x4641838b248a1cbf:0xcca0add4a7e85b82!2m2!1d11.1004153!2d60.1975501!1m5!1m1s0x46416d7e060312b:0x74c9d0fbf11562fd!2m2!1d10.6631133!2d59.9625944

Scandic Holmenkollen Park Hotel is located in the Holmenkollen area, up in the hills in the west side of Oslo. The hotel is approximately a 10-minute walk from the T-bane (metro) station Holmenkollen, which is served by line 1.

To get to the hotel from the airport, please take the train to Oslo S (Oslo Central Station), and switch here to T-bane line 1 direction Frognerseteren, until the Holmenkollen stop.

Train: From Oslo Gardermoen Airport to Oslo S (Central station): There are two train companies operating between Oslo Airport and Oslo S:
1. Flytoget (Airport Express Train): Every Airport Express Train stops at Oslo S. Journey time is 20 minutes. Depending on the time of day, the Flytoget departs every 10 or 15 minutes from Oslo Airport. A one-way ticket for the Flytoget costs 180 NOK.
2. NSB (Norwegian Rail Services): Several NSB train lines go to Oslo S. Journey time is 22 minutes.
   R10 direction Drammen
   R11 direction Skien
   L12 direction Kongsberg
   A one-way ticket for this NSB journey costs 92 NOK.

Please use the public transport journey planner on https://ruter.no/en/.

Metro: At Oslo S, please follow signs to the T-bane (metro) and take line 1 direction Frognerseteren until Holmenkollen. From Holmenkollen it is 650 meters to walk to Scandic Holmenkollen Park Hotel.

Taxi: Oslo Taxi, Norgestaxi, Taxi2 among others have special Airport Taxi offers, with fixed prices to and from Gardermoen. The price depends on the time of
day, number of passengers and where in Oslo you are travelling to/from. Check the taxi screens in the Arrivals Hall for prices.

If you want to take a taxi from the airport, you can go to the special taxi screens in the Arrivals Hall. There you can book a taxi, which will come driving up outside the Arrivals Hall. Please note that if you do not pre-book a taxi, the fixed rate may not apply.

**Official Symposium Language**
The official language of the Symposium will be English. No simultaneous translation will be available.

**Personal Invitation/Travel Documents**
Participants requiring visa are strongly advised to make their application in their home country at least two months before the intended date of travel. An invitation letter can be requested during registration to the Symposium and will be provided to duly registered participants. It is understood that such an invitation is intended to help potential delegates raising funds. The letter of invitation is not a commitment on the part of the Symposium to provide any financial support.

**Travel Insurance**
It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. ESCP and the other organizers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the Symposium participants and accompanying persons.

**Social Programme**
As an addition to the scientific program, a social program has been developed to give you the opportunity to explore the historical and natural beauties of Oslo, providing you with the perfect environment for open debate and network.

**Symposium Dinner**
The Symposium Dinner will take place at the restaurant of Scandic Holmenkollen Park Hotel on Thursday evening, 6 October 2016. The Conference dinner includes a visit to the Holmenkollen Ski Museum & Tower which is walking distance from the hotel. The ski jump is a historic landmark in the Norwegian consciousness, with more than a century of skiing competitions. Inside the ski jump is the Holmenkollen Ski Museum, the oldest of its kind in the world. The museum presents over 4,000 years of skiing history, Norwegian polar exploration artefacts and an exhibition on snowboarding and modern skiing.
observation deck on top of the jump tower offers panoramic views of Oslo. The panoramic view and fresh airs should build a great appetite before we stroll back to the hotel for the Symposium dinner. The brave ones can visit the ski simulator…. or even jump?


Symposium dinner tickets can be booked and purchased (price 500 NOK (ca.55 €) for those staying at the Scandic Holmenkollen Park Hotel and 900 NOK (ca 95 €) for those staying elsewhere. Dinner is booked through the registration system at https://goo.gl/RrFojb

Note that the number of places is limited to a maximum of 150 participants. Tickets will be sold on a first come, first served basis.

Welcome Reception
An informal Welcome Reception will take place at Oslo City Hall on the first day of the Symposium, on Wednesday evening, 5 October 2016.

About Oslo
Oslo is the oldest of the Scandinavian capitals, and its history goes back 1000 years, to the time when the first settlements were built at the inlet of the Oslo fjord. The capital of Norway is also its largest city. Oslo has over 600,000 inhabitants and covers 454 square kilometres, 242 of which are forests. The capital is the seat of the Norwegian Government and the Norwegian Parliament, and the home of Norway's King Harald V and Queen Sonja, The Royal Palace, is located at the end of Oslo's main street, Karl Johans gate.

If you need a timeout from the congress, visit cultural institutions such as
• The National Museum of Art, Architecture and Design
• The Astrup Fearnley Museum
• The Norwegian Opera and Ballet.

Location, geography and climate
Oslo is located innermost in the 100-kilometre-long Oslofjord, which is home to 40 islands. Over half of the municipality of Oslo is covered by forests and parks, making Oslo a truly green city. Oslo's climate is milder than its latitude might indicate. Summer temperatures often equal those of cities much further south, yet the winters are cold enough to make Oslo a great skiing destination.

To find out more about Oslo, please check out some of the following web-sites:

VisitOSLO A/S:
http://www.visitoslo.com
Tourist information on Oslo:
https://www.visitnorway.com/places-to-go/eastern-norway/oslo/
Information about Norway:
http://www.norway.org
To register for the Symposium please complete the online form at https://goo.gl/RrFojb. For further information please contact: Congress-Conference AS at e-mail: escp2016@ccnorway.no

<table>
<thead>
<tr>
<th>Category</th>
<th>Early Fee ** (until 31 July 2016)</th>
<th>Normal Fee (1 Aug to 19 Sept)</th>
<th>Late Fee (as of 20 Sept and on-site)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESCP Member</td>
<td>NOK 5100</td>
<td>NOK 6300</td>
<td>NOK 7400</td>
</tr>
<tr>
<td>Non-member</td>
<td>NOK 6250</td>
<td>NOK 7400</td>
<td>NOK 8600</td>
</tr>
<tr>
<td>Student *</td>
<td>NOK 2650</td>
<td>NOK 3100</td>
<td>NOK 3400</td>
</tr>
<tr>
<td>Accompanying Person</td>
<td>NOK 2100</td>
<td>NOK 2500</td>
<td>NOK 3000</td>
</tr>
</tbody>
</table>

### Symposium dinner

| Person staying at the venue hotel | NOK 500 | NOK 500 | NOK 500 |
| Person not staying at the venue hotel | NOK 900 | NOK 900 | NOK 900 |

*All prices including credit-card fee or bank-charges*

* Student fee is available only to those under-graduate students who do not yet have their pharmacy degree and are under 35 years of age. Students will be requested to submit a copy of their Student-ID before registration can be finalized.

** Presenters of accepted abstracts will have the possibility to register at the early registration fee until 12 September 2016.

**Participant’s registration fee includes**
- Admission to the scientific sessions from Wednesday, 5 October to Friday, 7 October 2016, unless otherwise stated
- Evening lecture on Tuesday, 4 October 2016, and Welcome Drinks
- Symposium documents, including badge and congress bag
- Final program and abstract book
- Access to the commercial exhibition and posters

**Welcome reception on Wednesday evening, 5 October 2016**
- Lunches and Coffee breaks
- Farewell Drinks after the Closing Ceremony
- Tourist documentation on Oslo.

**Accompanying person’s fee includes**
- Evening lecture on Tuesday, 4 October 2016, and Welcome Drinks
- Welcome reception on Wednesday evening, 5 October 2016
• Lunches and Coffee breaks  
• Farewell Drinks after the Closing Ceremony  
• Tourist documentation on Oslo. 

For detailed registration terms and conditions visit http://www.escpweb.org/Oslo

**Group Registrations**  
Groups with more than 10 participants could benefit from a Special Package. Please contact Congress-Conference AS for those special conditions: escp2016@ccnorway.no

**Continuing Education Credits**  
Pharmacists from Belgium, Croatia, Czech Republic, Finland, France, Germany, Italy, Netherlands, Norway, Portugal, Switzerland, and the United Kingdom can obtain continuing education credits for attending ESCP courses and symposia. For more information, please contact the ESCP International Office or visit the ESCP stand during the symposium.

**Confirmation**  
A letter of receipt will be sent to those who have completed the online registration form and settled their payment.

**Contact / Registration Cancellation / Modification terms and Conditions**  
Full payment is requested when registering (by credit card or by bank transfer). A confirmation e-mail will be sent after successful registration. Please check that you received this e-mail after you registered. All cancellations and changes to your original registration must be sent to Congress-Conference AS in writing (letter, or e-mail to escp2016@ccnorway.no.

Notification of cancellation must be submitted in writing to Congress-Conference AS: escp2016@ccnorway.no

- For any cancellation received until 15 August 2016 a penalty of 50% will apply.  
- For cancellations received between 16 August and 1 September 2016 a penalty of 75% will apply  
- From 2 September 2016, we regret but no refunds will apply.  
- All cancellations are subject to an administrative charge of NOK 500 in addition to the penalties mentioned above.  
- In the event of a no-show, hotel reservations will be cancelled after one night. No-shows will not be refunded.
**Hotel booking: General information**

Scandic Holmenkollen Park Hotel is the ESCP Symposium headquarters. For your convenience there is a large block of guest rooms available for ESCP 2016 attendees. Bookings for hotel rooms for the Scandic Holmenkollen Park Hotel are made directly through the local agent, Congress-Conference AS. Guest rooms are allocated on a first come, first served basis, and are subject to availability. Accommodation is provided on a single, double or twin occupancy basis. Double occupancy means one bed for two people sharing. Twin occupancy means two beds for two people sharing. If you should have requests for other dates than stated in the registration site, please contact Congress-Conference AS by e-mail: escp2016@ccnorway.no

**Hotel cancellation / modification terms and conditions**

Notification of cancellation must be submitted in writing to Congress-Conference AS: escp2016@ccnorway.no

- For any cancellation received until 15 August 2016 a penalty of 50% will apply.
- For cancellations received between 16 August and 1 September 2016 a penalty of 75% will apply
- From 2 September 2016, we regret but no refunds will apply.

All cancellations are subject to an administrative charge of NOK 500 in addition to the penalties mentioned above. In the event of a no-show, hotel reservations will be cancelled after one night. No-shows will not be refunded.

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Category</th>
<th>Single room Price per night</th>
<th>Double/Twin room Price per night</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scandic Holmenkollen Park Hotel</td>
<td>4****</td>
<td>1410,- NOK</td>
<td>2360,- NOK</td>
</tr>
<tr>
<td>Smart Hotel Oslo</td>
<td>3***</td>
<td>895,- NOK</td>
<td>1195,- NOK</td>
</tr>
</tbody>
</table>

* Rates are in Norwegian Crowns (NOK) per room, per night, including breakfast, VAT and taxes. These special rates are available only if booking is made and paid through Congress-Conference AS.*
Oslo City Center with hotel locations
The First Attendance Meeting
Wednesday, 5 October, 12:00 – 12:30.
For those participants who attend an ESCP symposium for the first time a meeting will be organized where members of ESCP Committees and SIGs will be present to give the First Attendance Participants a better insight into the activities and structure of ESCP and the benefits of membership.

***

The Steve Hudson Memorial Lecture
Wednesday, 5 October, 11:30 – 12:00
Professor Steve Hudson passed away on November 21st, 2010. Steve’s dedication to education and developing young minds was one of his greatest legacies. He introduced a clear vision on what he called Integrated Pharmaceutical Care, a philosophy of practice to the advancement of patient care in which the pharmacist, patient and physician collaborate in assessing patient needs, determining care issues and developing a care plan. By doing so Steve developed lifelong friendships throughout the world.

We believe that the greatest tribute our profession can pay to Steve is to continue to develop our hospital and community pharmacy practice to realize his vision. Therefore the General Committee has decided to install the Steve Hudson Lecture, as an integral part of ESCP’s annual meeting. For this lecture ESCP invites a speaker, who will be able to show his or her work in Pharmaceutical Care Practice, in particular to illustrate the achievements in pharmacy practice built on Steve’s vision.
Scientific Programme
Tuesday, 4 October 2016

Masterclass of Excellence in Pharmacy  9:00 – 16:30
by ESCP Research Committee

Evening Opening Lecture  18:00 – 18:45
by Dr. Magne Nylenna,
Director of The Norwegian Knowledge Centre for the Health Services.

WELCOME DRINKS AT SCANDIC HOLMENKOLLEN PARK HOTEL 18:45 – 19:30
MASTERCLASS OF EXCELLENCE IN QUALITATIVE RESEARCH

“Getting started with qualitative research: from research questions to dissemination”

Tutors: Marcel Bouvy, Netherlands and Sofia Kälvemark Sporrong, Denmark

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00–09.30</td>
<td>Introduction to qualitative research, place among other types of research, relevance</td>
</tr>
<tr>
<td>09.30–10.15</td>
<td>Analyzing qualitative data</td>
</tr>
<tr>
<td>10.15–10.30</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:30–11:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.00–12.00</td>
<td>Theory on three qualitative methods: Focus Groups, Interviews, Semi-Qualitative methods (q-study)</td>
</tr>
<tr>
<td>12:00–13.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>13.00–14.30</td>
<td>Group work: Three transcripts from Focus Groups, Interviews and Semi-Qualitative methods. Group discussions of research questions and analysis of the texts based on the research methodology.</td>
</tr>
<tr>
<td>14.30–15.00</td>
<td>Analysis of qualitative research: notes making, taping, audio (ATLAS, Nvivo)</td>
</tr>
<tr>
<td>15.00–15.15</td>
<td>Publishing qualitative research</td>
</tr>
<tr>
<td>15.15–16.00</td>
<td>&quot;Elevator Pitch&quot; presentations by the different groups and plenary discussion</td>
</tr>
<tr>
<td>16.00–16.30</td>
<td>Evaluation and final comments</td>
</tr>
</tbody>
</table>

About the tutors

Marcel Bouvy is professor of pharmaceutical care and research manager at SIR institute for Pharmacy Practice and Policy in Leiden, in cooperation with Utrecht University. He is past president of the Scientific Section of Dutch Community Pharmacists (WSO), founding member of the European Society for Patient Adher-
ence, Compliance and Persistence (ESPACOMP) and editorial board member of IJCP. As an active community pharmacist, his research focus on patient adherence, medication safety, including observational methods and evaluation of pharmacy interventions. Marcel has attended ESCP conferences for 20 years, and is member of the ESCP Research committee.

**Sofia Kälvenmark Sporrong** is associate professor and research group leader in social pharmacy at the University of Copenhagen. She has a social science background and has a versatile experience with qualitative research methodology. She PhD in social medicine from Uppsala University focused on moral distress in the health care sector. She does research on the pharmacy professions e.g. pharmacy policy, pharmacy practice and drug communication. In this Masterclass, she draw upon experience in social science methods and health care ethics.

**Venue**  
Oslo and Akershus University College, City centre Oslo.

**Registration**  
http://www.escpweb.org/Oslo

**Maximum**  
30 participants

**Separate registration/ registration fees**  
Additional fee for registration if also registered with ESCP Symposium

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Masterclass only, ESCP member</td>
<td>150 €</td>
</tr>
<tr>
<td>Masterclass only, ESCP non-member</td>
<td>200 €</td>
</tr>
<tr>
<td>Additional fee for registration with ESCP Symposium, ESCP member</td>
<td>120 €</td>
</tr>
<tr>
<td>Additional fee for registration with ESCP Symposium, ESCP non-member</td>
<td>150 €</td>
</tr>
</tbody>
</table>

**EVENING OPENING LECTURE AND WELCOME DRINKS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00–18:45</td>
<td>Inequalities in access to information</td>
</tr>
<tr>
<td></td>
<td><strong>Magne Nylenna, Norway</strong></td>
</tr>
<tr>
<td>18:45–19:30</td>
<td>Welcome Drinks at Scandic Holmenkollen Park Hotel</td>
</tr>
</tbody>
</table>
Scientific Programme
Wednesday, 5 October 2016
<table>
<thead>
<tr>
<th>Time</th>
<th>Morning Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15–09:45</td>
<td><strong>Opening Ceremony</strong>&lt;br&gt;ESCP President <em>Markus Lampert, Switzerland</em>&lt;br&gt;Symposium President <em>Frank Jørgensen, President NSF</em></td>
</tr>
<tr>
<td>09:45–11:30</td>
<td><strong>Morning Plenary Session</strong>&lt;br&gt;<em>L 1.1 Inequalities and access to health care: lessons to learn from experiences and challenges in Belgium.</em>&lt;br&gt;<em>Chairs:</em> TBA&lt;br&gt;<em>Speaker:</em> Jo De Cock, Director-General of the Belgian National Social and Health security Dep., BE</td>
</tr>
<tr>
<td>10:30–11:00</td>
<td><strong>Coffee Break– Poster viewing – Exhibition</strong></td>
</tr>
<tr>
<td>11:00–11:30</td>
<td><strong>L 1.2: Pharmacist experiences of health and ethnic inequalities: a case study of diabetes management</strong>&lt;br&gt;<em>Speaker:</em> Alia Gilani, South Asian Health Foundation, Diabetes and primary care journal, NHS Glasgow</td>
</tr>
<tr>
<td>11:30–12:00</td>
<td><strong>Steve Hudson Memorial Lecture.</strong> <em>Speaker:</em> Rose Marie Parr, Chief Pharmaceutical Officer at the Scottish Government.</td>
</tr>
<tr>
<td>12:00–12:30</td>
<td><strong>First Attendance Meeting</strong></td>
</tr>
<tr>
<td>12:00–13:30</td>
<td><strong>Sponsored satellite symposium</strong></td>
</tr>
<tr>
<td>12:00–13:30</td>
<td><strong>Lunch – Poster viewing – Exhibition</strong></td>
</tr>
</tbody>
</table>

**INEQUALITY IN HEALTH**
### INEQUALITY IN HEALTH

<table>
<thead>
<tr>
<th>Time</th>
<th>Afternoon Programme</th>
<th>Parallel Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–15:30</td>
<td>Workshops</td>
<td>(summaries on page 34-48)</td>
</tr>
<tr>
<td></td>
<td>L 1.3: Smoking including interactions with medicines</td>
<td>Speaker: Grainne Cousins, RCSI School of Pharmacy, Dublin, Ireland,</td>
</tr>
<tr>
<td></td>
<td>L 1.4: Alcohol including interactions with medicines</td>
<td>Speaker: Maria Dobrinas Bonazzi, Pharmacie des hôpitaux de l'Est Lémanique, CH</td>
</tr>
<tr>
<td></td>
<td>Round Table Discussion</td>
<td></td>
</tr>
<tr>
<td>15:30–16:00</td>
<td>Coffee Break– Poster viewing – Exhibition</td>
<td></td>
</tr>
<tr>
<td>16:00–18:00</td>
<td>Oral Communications I</td>
<td></td>
</tr>
<tr>
<td>16:00–18:00</td>
<td>Poster Discussion Forum I</td>
<td></td>
</tr>
<tr>
<td>16:00–18:00</td>
<td>Workshops</td>
<td>(summaries on page 34-48)</td>
</tr>
<tr>
<td>19:00–20:30</td>
<td>Reception and guided tour of Oslo City Hall</td>
<td></td>
</tr>
</tbody>
</table>
Holmenkollbakken, famous ski jumping hill since 1892 in Holmenkollen, near Oslo
Scientific Programme
Thursday, 6 October 2016
### ACCESS TO MEDICINES

<table>
<thead>
<tr>
<th>Time</th>
<th>Morning Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45–12:00</td>
<td><strong>Morning Plenary Session</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chairs</em>: TBA</td>
</tr>
<tr>
<td>08:45–09:00</td>
<td><strong>L 2.1 The patient perspective.</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker</em>: Pauline Evers, The Netherlands.</td>
</tr>
<tr>
<td>09:00–09:25</td>
<td><strong>Pharmacotherapy update: Biosimilars – what should clinical pharmacists know?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker</em>: TBA</td>
</tr>
<tr>
<td>09:25–09:45</td>
<td><strong>L 2.2: Regulatory perspective on new and expensive medicines.</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker</em>: Karsten Bruins Slot, the Norwegian Medicines Agency, Oslo, Norway.</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td><strong>Coffee Break– Poster viewing – Exhibition</strong></td>
</tr>
<tr>
<td>10:15–12:00</td>
<td><strong>The new expensive medicines-how to prioritize?</strong></td>
</tr>
<tr>
<td></td>
<td><strong>L 2.3: Costs and benefits of treating patients with expensive medication.</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker</em>: Hans Olav Melberg, University of Oslo, Norway</td>
</tr>
<tr>
<td></td>
<td><strong>L 2.4: How NICE appraisal supports the rational access to new and expensive medication.</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker</em>: Olivia Wu, HEHTA, Institute of Health &amp; Wellbeing, Univ. Glasgow, UK</td>
</tr>
<tr>
<td></td>
<td><strong>L 2.5: The balance between innovation and priority setting for the innovative pharmaceutical industry.</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker</em>: Ånen Ringard, The Norwegian Pharm. Industry Association, Oslo, Norway</td>
</tr>
<tr>
<td></td>
<td><strong>Panel discussion.</strong></td>
</tr>
<tr>
<td></td>
<td><em>Moderator</em>: Moira Kinnear, Head of Education, R&amp;D at NHS Lothian, Edinburgh, UK</td>
</tr>
<tr>
<td>12:00–13:30</td>
<td><strong>Sponsored satellite symposium</strong></td>
</tr>
<tr>
<td>12:00–13:30</td>
<td><strong>Lunch – Poster viewing – Exhibition</strong></td>
</tr>
</tbody>
</table>
## ACCESS TO MEDICINES

<table>
<thead>
<tr>
<th>Time</th>
<th>Afternoon Programme</th>
<th>Parallel Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–15:30</td>
<td><strong>Workshops</strong></td>
<td><em>(summaries on page 34–48)</em></td>
</tr>
<tr>
<td>13:30–15:30</td>
<td><strong>Afternoon Plenary Session</strong>&lt;br&gt;<strong>Advanced therapies</strong>&lt;br&gt;<em>Chairs: TBA</em>&lt;br&gt;&lt;br&gt;<strong>L 2.6: Advanced therapy – the future of immunotherapy in rheumatology</strong>&lt;br&gt;<em>Speaker: Siri Lillegraven, The hospital at Diakonhjemmet, Norway</em>&lt;br&gt;&lt;br&gt;<strong>L 2.7: The role of the clinical pharmacist in advanced therapy.</strong>&lt;br&gt;<em>Speaker: Benoit Allenet, Centre Hospitalier Universitaire Grenoble Alpes, France</em></td>
<td>&lt;br&gt;<strong>Round Table Discussion</strong></td>
</tr>
<tr>
<td>15:30–16:00</td>
<td><strong>Coffee Break– Poster viewing – Exhibition</strong></td>
<td>&lt;br&gt;<strong>16:00–18:00</strong>&lt;br&gt;<strong>Oral Communications II</strong>&lt;br&gt;<strong>16:00–18:00</strong>&lt;br&gt;<strong>Poster Discussion Forum II</strong>&lt;br&gt;<strong>16:00–18:00</strong>&lt;br&gt;<strong>Workshops</strong> <em>(summaries on page 34–48)</em>&lt;br&gt;<strong>18:00–19:00</strong>&lt;br&gt;<strong>General Assembly</strong>&lt;br&gt;<strong>20:00–</strong>&lt;br&gt;<strong>Conference Dinner at Oslo Ski Museum and Holmenkollen Park Hotel</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Masterclass in qualitative research 09:00-16:30</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&quot;Getting started with qualitative research: from research questions to dissemination.&quot; Marcel Bouvy, Netherlands; Sofia Kälvemark Sporrong, Denmark</td>
<td></td>
</tr>
</tbody>
</table>

**Wednesday, 5 October**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Opening Ceremony ESCP President Markus Lampert, CH Symposium President Frank Jørgensen, President NSF</td>
</tr>
<tr>
<td>09:00</td>
<td>L 1.1: Inequalities and access to health care: lessons to learn from experiences and challenges in Belgium. Jo De Cock, BE</td>
</tr>
<tr>
<td>09:45</td>
<td>L 1.2: Pharmacist experiences of health and ethnic inequalities: a case study of diabetes management. Alia Gilani, UK</td>
</tr>
<tr>
<td>10:00</td>
<td>Morning Session: Inequality in Health Chaired by TBA</td>
</tr>
<tr>
<td>10:15</td>
<td>L 1.3: Smoking including interactions with medicines. Grainne Cousins, IE</td>
</tr>
<tr>
<td>10:30</td>
<td>L 1.4: Alcohol including interactions with medicines. Maria Dobrinas Bonazzi, CH</td>
</tr>
<tr>
<td>11:00</td>
<td>Coffee Break – Poster viewing – Exhibition</td>
</tr>
<tr>
<td>11:15</td>
<td>L 1.5: The role of the clinical pharmacist in advanced therapy. Benoit Allenet, FR</td>
</tr>
<tr>
<td>11:30</td>
<td>L 1.6: Pharmacist experiences of health and ethnic inequalities: a case study of diabetes management. Joanna Cousins, IE</td>
</tr>
<tr>
<td>11:45</td>
<td>Steve Hudson Memorial Lecture Rose Marie Parr, UK</td>
</tr>
<tr>
<td>12:00</td>
<td>First Attendance Meeting Sponsored satellite symposium Lunch – Poster viewing Exhibition</td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch – Poster viewing – Exhibition</td>
</tr>
<tr>
<td>13:00</td>
<td>Afternoon Session: Clinical pharmacists altering addictive behavior. Chaired by TBA</td>
</tr>
<tr>
<td>13:30</td>
<td>L 2.1: The patient perspective. Jo De Cock, BE</td>
</tr>
<tr>
<td>14:00</td>
<td>L 2.2: Regulatory perspective on new and expensive medication. Hans Olav Melberg, NO</td>
</tr>
<tr>
<td>14:30</td>
<td>L 2.3: Costs and benefits of treating patients with expensive medication. Olivia Wu, UK</td>
</tr>
<tr>
<td>15:00</td>
<td>Round Table Discussion</td>
</tr>
<tr>
<td>15:30</td>
<td>Coffee Break – Poster viewing – Exhibition</td>
</tr>
<tr>
<td>16:00</td>
<td>Oral Communications I Poster Discussion Forum I Workshops (p.34–48) Workshops (p.34–48)</td>
</tr>
<tr>
<td>16:30</td>
<td>Workshops (p.34–48) Workshops (p.34–48)</td>
</tr>
<tr>
<td>17:00</td>
<td>Oral Communications II</td>
</tr>
<tr>
<td>17:30</td>
<td>Evening Lecture: Inequalities in access to information Magne Nylenna, NO Welcome Drinks Scandic Holmenkollen Park Hotel</td>
</tr>
<tr>
<td>18:00</td>
<td>Conference Dinner at ESCP General Assembly</td>
</tr>
<tr>
<td>18:30</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td>19:00</td>
<td>lor Communications I Poster Discussion Forum I Workshops (p.34–48) Workshops (p.34–48)</td>
</tr>
<tr>
<td>19:30</td>
<td>Workshops (p.34–48) Workshops (p.34–48)</td>
</tr>
</tbody>
</table>
| 20:00 | }
### Thursday, 6 October

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–09:25</td>
<td>Pharmacotherapy update: Biosimilars:</td>
</tr>
<tr>
<td>09:25–09:45</td>
<td>L 2.2: Regulatory perspective on new and expensive medicines. Karlsten Bruins Slot, NO</td>
</tr>
<tr>
<td>09:45–10:00</td>
<td>Coffee Break – Poster viewing – Exhibition</td>
</tr>
<tr>
<td>10:00–10:45</td>
<td>L 2.3: Costs and benefits of treating patients with expensive medication. Hans Olav Melberg, NO</td>
</tr>
<tr>
<td>10:45–11:30</td>
<td>L 2.4: How NICE appraisal supports the rational access to new and expensive medication. Olivia Wu, UK</td>
</tr>
<tr>
<td>11:30–12:00</td>
<td>L 2.5: The balance between innovation and priority setting for the innovative pharmaceutical industry. Anen Ringard, NO</td>
</tr>
<tr>
<td></td>
<td>Panel discussion Moderator: Moira Kinnear, UK</td>
</tr>
<tr>
<td>12:00–12:30</td>
<td>Lunch – Poster viewing – Exhibition</td>
</tr>
<tr>
<td>12:30–13:00</td>
<td>Poster viewing – Exhibition</td>
</tr>
<tr>
<td>13:00–13:30</td>
<td>Workshops (p.34–48)</td>
</tr>
<tr>
<td></td>
<td>WS02</td>
</tr>
<tr>
<td></td>
<td>WS03</td>
</tr>
<tr>
<td></td>
<td>WS04</td>
</tr>
<tr>
<td></td>
<td>WS07</td>
</tr>
<tr>
<td></td>
<td>WS08</td>
</tr>
<tr>
<td></td>
<td>WS09,1</td>
</tr>
<tr>
<td></td>
<td>WS11</td>
</tr>
<tr>
<td></td>
<td>WS18</td>
</tr>
<tr>
<td>13:30–14:00</td>
<td>L 2.6: Advanced therapy – the future of immunotherapy in rheumatology. Siri Lillegraven, NO</td>
</tr>
<tr>
<td>14:00–14:30</td>
<td>L 2.7: The role of the clinical pharmacist in advanced therapy. Benoit Allenet, FR</td>
</tr>
<tr>
<td>14:30–15:00</td>
<td>Poster Discussion Forum II</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>Lunch – Poster viewing – Exhibition</td>
</tr>
<tr>
<td>15:30–16:00</td>
<td>Closing Ceremony &amp; Award Winners</td>
</tr>
</tbody>
</table>

### Friday, 7 October

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45–09:00</td>
<td>L 3.1: Empowering children as medicines users. Katri Hämeen-Anttila, FI</td>
</tr>
<tr>
<td>09:00–09:15</td>
<td>L 3.2: Type 2 diabetes in children and adolescents. Sule Apikoglu-Rabius, Turkey.</td>
</tr>
<tr>
<td>09:15–09:30</td>
<td>L 3.3: Good psychopharmacology practice in ADHD. Hans Mulder, NL</td>
</tr>
<tr>
<td>09:45–10:30</td>
<td>Coffee Break – Poster viewing – Exhibition</td>
</tr>
<tr>
<td>10:00–10:15</td>
<td>Sponsored satellite symposium</td>
</tr>
<tr>
<td>10:30–11:00</td>
<td>Oral Communications III</td>
</tr>
<tr>
<td>11:00–11:15</td>
<td>Poster Discussion Forum III</td>
</tr>
<tr>
<td>11:15–11:30</td>
<td>Workshops (p.34–48)</td>
</tr>
<tr>
<td></td>
<td>WS01</td>
</tr>
<tr>
<td></td>
<td>WS03</td>
</tr>
<tr>
<td></td>
<td>WS07</td>
</tr>
<tr>
<td></td>
<td>WS08</td>
</tr>
<tr>
<td></td>
<td>WS10</td>
</tr>
<tr>
<td></td>
<td>WS12</td>
</tr>
<tr>
<td></td>
<td>WS18</td>
</tr>
<tr>
<td>11:30–11:45</td>
<td>L 3.4: Gut microbiota: Recipient for and donor of antibiotic resistant microbes and genes. Tore Midtvedt, NO</td>
</tr>
<tr>
<td>11:45–12:00</td>
<td>L 3.5: Tackling Antibiotic Resistance - the role of clinical pharmacists ... Hege Salvesen Blix, NO</td>
</tr>
<tr>
<td>12:00–12:30</td>
<td>Lunch – Poster viewing – Exhibition</td>
</tr>
<tr>
<td>12:30–13:00</td>
<td>Closing Ceremony &amp; Award Winners</td>
</tr>
</tbody>
</table>

### Workshops (p.34–48)

**WS02**

**WS03**

**WS04**

**WS07**

**WS08**

**WS09,1**

**WS11**

**WS18**

### ESCP General Assembly

Oslo Ski Museum and Holmenkollen Park Hotel
Scientific Programme
Friday, 7 October 2016

Oslo City Hall or Oslo rådhus (1931-1950)
by the Norwegian architects Arnstein Arneberg and Magnus Poulsson
LONG-TERM CONDITIONS IN CHILDREN. ANTIMICROBIAL RESISTANCE

<table>
<thead>
<tr>
<th>Time</th>
<th>Morning Programme</th>
</tr>
</thead>
</table>
| 08:45–12:00   | **Morning Plenary Session**  
Long-term conditions in children  
*Chairs:* TBA  
**L 3.1:** Empowering children as medicines users.  
*Speaker:* Katri Hämeeen-Anttila, PhD, Adjunct Professor and Development Manager, the Finnish Medicines Agency: Empowering children as medicines users  
**L 3.2:** Type 2 diabetes in children and adolescents.  
*Speaker:* Sule Apikoglu-Rablus, Associate Prof., Marmara University, Faculty of Pharmacy, Turkey.  
**L 3.3:** Good psychopharmacology practice in ADHD.  
*Speaker:* Hans Mulder, Department of Clinical Pharmacy, Wilhelmina Hospital, Assen, the Netherlands |
| 10:30–11:00   | Coffee Break– Poster viewing – Exhibition |
| 11:00–12:00   | **Antimicrobial Resistance**  
**L 3.4:** Gut microbiota: Recipient for and donor of antibi-otic resistant microbes and genes.  
*Speaker:* Tore Midtvedt, Professor emeritus, Norway  
**L 3.5:** Tackling Antibiotic Resistance - the role of clinical pharmacists in the appropriate treatment of infections.  
*Speaker:* Hege Salvesen Blix, Professor, Norwegian Institute of Public Health, Oslo, Norway |
| 12:00–13:30   | Lunch – Poster viewing – Exhibition |
| Time          | Afternoon Programme | Parallel Sessions |
| 13:30–15:30   | **Oral Communications III** |
| 13:30–15:30   | **Poster Discussion Forum III** |
| 13:30–15:30   | **Workshops** (*summaries on page 34–48*) |
| 15:30–16:00   | **Closing Ceremony and Farewell Drinks** |
Workshops

Workshop lasts for 2 hours for up to 30 participants. Participants sign up at the ESCP conference desk.
<table>
<thead>
<tr>
<th>Time</th>
<th>Workshops</th>
</tr>
</thead>
</table>
| 13:30–15:30      | **WS01**: Successful Scientific Writing: getting conference abstracts accepted  
|                  | **WS05**: Improvements in quality of care with the "Model for Improvement"  
|                  | **WS12**: Controversy and consensus of integrating a clinical pharmacist into practice  
|                  | **WS13**: Skills set development for Advanced Clinical Pharmacy Practitioners  
|                  | **WS14**: What can a clinical pharmacist do to reduce medication waste?  
|                  | **WS16**: Contemporary approach to acute post-operative pain  
|                  | **WS17**: How can we optimize clinical pharmacy efficiency with limited resources?  
|                  | **WS19**: Less is more? Deprescribing in older polypharmacy patients  |
| 16:00–18:00      | **WS02**: Successful Scientific Writing: original research papers  
|                  | **WS06**: Communicating with children  
|                  | **WS13**: Skills set development for Advanced Clinical Pharmacy Practitioners  
|                  | **WS14**: What can a clinical pharmacist do to reduce medication waste?  
|                  | **WS15**: Motivational interviewing: A method for clinical pharmacists to change  
|                  | **WS16**: Contemporary approach to acute post-operative pain  
|                  | **WS19**: Less is more? Deprescribing in older polypharmacy patients  |

Workshop last for 2 hours for up to 30 participants. Participants sign up at the ESCP conference desk.
<table>
<thead>
<tr>
<th>Time</th>
<th>Workshops</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–15:30</td>
<td><strong>WS02</strong>: Successful Scientific Writing: original research papers</td>
</tr>
<tr>
<td></td>
<td><strong>WS03</strong>: Planning and running a workshop</td>
</tr>
<tr>
<td></td>
<td><strong>WS04</strong>: Total Parenteral Nutrition– an IT approach</td>
</tr>
<tr>
<td></td>
<td><strong>WS07</strong>: Tackling inequalities in access to research</td>
</tr>
<tr>
<td></td>
<td><strong>WS08</strong>: Guidelines for pharmaceutical care: nuisance or necessity?</td>
</tr>
<tr>
<td></td>
<td><strong>WS09</strong>, p1: SIMPATHY, part 1</td>
</tr>
<tr>
<td></td>
<td><strong>WS11</strong>: How to convince the doctor</td>
</tr>
<tr>
<td></td>
<td><strong>WS18</strong>: Administration of vaccines and injectable drugs by pharmacists</td>
</tr>
<tr>
<td>16:00–18:00</td>
<td><strong>WS06</strong>: Communicating with children</td>
</tr>
<tr>
<td></td>
<td><strong>WS05</strong>: Improvements in quality of care with the &quot;Model for Improvement&quot;</td>
</tr>
<tr>
<td></td>
<td><strong>WS09</strong>, p2: SIMPATHY, part 2</td>
</tr>
<tr>
<td></td>
<td><strong>WS10</strong>: Cultural competence: pharmacist communication for a global population</td>
</tr>
<tr>
<td></td>
<td><strong>WS11</strong>: How to convince the doctor</td>
</tr>
<tr>
<td></td>
<td><strong>WS15</strong>: Motivational interviewing: A method for clinical pharmacists to change</td>
</tr>
<tr>
<td></td>
<td><strong>WS17</strong>: How can we optimize clinical pharmacy efficiency with limited resources?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshops</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–15:30</td>
<td><strong>WS01</strong>: Successful Scientific Writing: getting conference abstracts accepted</td>
</tr>
<tr>
<td></td>
<td><strong>WS03</strong>: Planning and running a workshop</td>
</tr>
<tr>
<td></td>
<td><strong>WS07</strong>: Tackling inequalities in access to research</td>
</tr>
<tr>
<td></td>
<td><strong>WS08</strong>: Guidelines for pharmaceutical care: nuisance or necessity?</td>
</tr>
<tr>
<td></td>
<td><strong>WS10</strong>: Cultural competence: pharmacist communication for a global population</td>
</tr>
<tr>
<td></td>
<td><strong>WS12</strong>: Controversy and consensus of integrating a clinical pharmacist into practice</td>
</tr>
<tr>
<td></td>
<td><strong>WS18</strong>: Administration of vaccines and injectable drugs by pharmacists</td>
</tr>
</tbody>
</table>
WS01
Successful Scientific Writing: getting conference abstracts accepted.
ESCP Communication Committee workshop proposal
Moderators: Dr. Carole Kaufmann, Switzerland. Member of the Communication Committee of ESCP and member of the Scientific Committee
Dr. Anne Gerd Granas, Norway. Member of the General Committee of ESCP and member of the Organising Committee
Background: There are several possible formats for written scientific information such as abstracts or scientific articles. Writing a good conference abstract is important because it may lead to having an (oral) presentation at a conference. Writing conference abstracts that will be accepted for presentation at a conference is a challenging experience. Apart from writing a condensed text, that represents the study well, there are a number of other important aspects that will facilitate acceptance. This workshop will focus on abstracts, such as expected by ESCP. But participants will also discuss more general and ethical considerations about submitting abstracts, such as authorships and responsibilities. After an introduction, the participants will study and discuss examples of the different stages of abstracts in smaller groups.
Learning objectives: After the workshop, the participant should be able to:
- Understand the structure and elements of a quality conference abstract;
- Select an appropriate conference and presenter for the study;
- Understand the differences between the different scientific presentation platforms;

WS02
Successful Scientific Writing: original research papers. An ESCP workshop.
ComCom workshop proposal (2) for ESCP
Moderators: Elena Galfrascoli, Italy. Member of the ESCP Communication Committee. ASST Fatebenefratelli Sacco, Milano.
Dr. J.W. Foppe van Mil, the Netherlands. Member of the ESCP SIG-MI and the Communication Committee of ESCP, Editor-in-Chief of the International Journal of Clinical Pharmacy (previously PWS).
Background: The results of scientific research are only valuable for society, if they can be shared with others in an understandable written or oral format. There are several possible formats for written information, such as abstracts or scientific articles. Writing research papers that can be accepted by a peer reviewed journal, can be a challenging experience. There are a number of important aspects that authors should pay attention to, and that will facilitate acceptance.
Aim: Aim of the workshop is to discuss with the participants different examples of scientific papers, to make them able to write and judge a scientific paper, and also to select the appropriate journal for the publication.
Learning Objectives: After the workshop, the participant should be able to:
- Understand the structure and elements of a quality scientific paper;
- Select an appropriate journal for his publication(s);
- Understand the differences between the different peer reviewed scientific journals;

Content and Structure: A presentation will introduce participants to the content of the workshop, focusing on the aim of writing a full research article, and the structure of a scientific article. The reason behind the different sections of articles will be explained.
The workshop will especially focus on scientific articles in the format for the International Journal of Clinical Pharmacy but most other scientific journals have similar compulsory formats. After an introduction, the participants will study and discuss examples of the different stages of scientific papers in smaller groups, the selec-
Workshops

Workshop Abstracts

WS03
Planning and running a workshop
Moderated by members of the ESCP Education Committee
Moira Kinnear and Vera Jordan-von Gunten

Background: A workshop requires participants to interact with some purposeful activity to achieve defined learning outcomes. Workshops provide an environment for participants to share ideas and learn from each other. Most people learn more from active involvement than from passively listening, therefore talking about a topic, role play or practical sessions are considered valuable learning experiences in clinical pharmacy. It’s important to be clear about what can be achieved in a workshop and several factors need to be considered in the design. These include content, learning outcomes, tasks, structure, timing, group size, environment and resources.

Aim: The aim of this workshop is to consider tips for inexperienced workshop facilitators to support future planning of successful workshops.

Learning Objectives: At the end of the workshop, participants will be able to
- Describe how people learn – The Learning Pyramid
- Prepare a workshop plan including a schedule of activities and learning outcomes
- Create group exercises achievable within a planned schedule and resources
- Describe workshop facilitation skills.

Content and Structure: Introduction (5 mins)
Groups will be provided with copies of The Learning Pyramid for discussion in their groups.

Task 1: Participants will be asked to reflect on previous learning experiences and consider in the context of the way most people learn. (10 mins)
Facilitated discussion: Experiences will be shared across groups. (10 mins)

Task 2: Participants will be asked to share their experiences of workshop facilitation (either as a facilitator or as a participant) and suggest skills required for workshop facilitation (20 mins)
Facilitated discussion: Groups share considerations (10 mins)

Task 3: Each group will be asked to agree the content for a workshop, formulate learning outcomes and design a schedule of activities. (30 mins)
Facilitated discussion: These will be shared across the groups and feedback provided (30 mins)
Summary and close (5 mins)

WS04
Total Parenteral Nutrition– an IT approach for prescribing, compounding and strategies for continuous quality improvement and patient safety.
Moderator(s), with affiliations:
Dr. Maria Skouroliakou, diatrofi@iaso.gr, Panos Papandreou PharmD, papandreou.panos@gmail.com

Background: The preparation of a daily formula for TPN for a patient is a complex procedure. Numerous factors such as weight, age, clinical state, environmental conditions (type of incubator, phototherapy etc.) and transition of care should be taken into consideration. Furthermore the variation amongst prescribing methods has lead to increased adverse events and strengthens the need for a safe prescribing of this therapy. Continuous quality improvement is a paramount aspect in health care and is a key feature in our clinical work as a pharmacist. Exploring appropriate strategies to integrate quality improvement will directly impact patient safety and allow for better communication between health care providers and clinicians.

Aim: The goal of the workshop is to provide the advantages of standardized prescribing automated compounding, and continuous quality improvement strategies that aid in:
greater accuracy of volumes transferred, fewer manipulation of the final container, less labor-intensive, availability of safeguards to ensure correct source solution placement and quantitative methods to verify volume transferred. Furthermore, it will strengthen the interdisciplinary approach of patient care between health care providers. It will function as a means to decrease adverse reactions and med errors and allow for continuous quality improvements and data collection for research purposes.

**Learning Objectives:**
1. Total Parenteral Nutrition (TPN) from neonates to adults (inpatient-outpatient)
2. Assessment of common adverse events associated with TPN therapy
3. Analysis of importance of standardized protocols and prescription forms
4. Define continuous quality improvement (CQI) and how it applies to clinical care and patient safety.
5. Describe Electronic health record (EHR) implementations and practice improvement strategies.
6. Identify a conceptual framework to consider when implementing CQI techniques in a practice setting.
7. Analyze Total Parenteral Nutrition protocols grouped by age.
8. Assessment of Standardized physician order/prescription template
9. Determination of workflow model involving patient care (from written prescription to dispensing medication to patient)
10. Compare and contrast between ready to use TPN and patient specific compounded solutions

**Content and Structure:** The workshop will give an overview in parenteral nutrition principles. Data collected from literature and clinical experience of the workshops’ facilitators in collaboration with other health care prescribers, were the basis for the creation of protocols. The protocols differentiate according to the age of infants, children and adolescents. To assist in the difficult task of formulation and administration protocol-based TPN, an IT approach has been adopted. An assessment of this IT approach will follow presenting specifics on the aid on TPN prescription and production. An analysis and assessment clinical features will be made with the purpose of exposing and understanding common adverse events associated with TPN prescribing, compounding and dispensing. The association between the use of IT and continuous quality improvement strategies will be outlined and presented in addition to the power of data collection by means of tracking patients TPN regimen and their correlating clinical outcomes. Finally the need for individualized prescription versus ready to use will be discussed.

**WS05**

**Major systematic improvements in quality of care with the ‘Model for Improvement’**

**Moderators, with affiliations:**
Dorthe Vilstrup Tomsen, M.Sc. Pharm. (dorthe.vilstrup.tomsen.01@regionh.dk)
Signe Kristensen, M.Sc. Public Health (signe.kristensen.02@regionh.dk)

**Background:** The Model for Improvement (MI) is developed by IHI (Institute for Healthcare Improvement) in Cambridge, MA. The Model is used in different health care settings and can address different levels of improvement work, from developing new working methods and services to setting organizational improvement efforts into an effective framework. MI is a way of creating sustainable changes in a short span of time. A systematic approach to breaking down the subject matter, and identifying “the best next move”, the model enables a success combination of “quick-wins” and “fail-fast”. The model is grounded in practice and the strengths lies within its focus on creating and testing changes within the local setting before
the actual implementation. By testing (going through the PDSA-cycle) you get feedback directly from the frontline personnel and you become able to adjust the change so it makes sense in the present setting. Hereby you ensure that the change is useful and relevant in the context which is an important element to ensure implementation and to sustain the changes made. Working by this method also makes it possible to show that the changes you create are actual improvements and are of benefit to the patients.

**Aim:** The aim of the workshop is to gain “hands-on” knowledge on the “Model for Improvement” and to get familiar with the tools used in the development, implementation and how to gain sustainability in pharmaceutical care services.

**Learning objectives:**
- To get to know the Model of Improvement
- To design an improvement project
- To be able to define and carry out PDSA’s (Improvement cycles)
- To understand the basics of Statistical Process Control

**Activities in the workshop:** During the workshop, the model will be introduced, and participants will be encouraged to approach their own project idea with the tools offered. New tools and concept will be introduced based on examples from real life.

**WS06**

**Communicating with Children**

*Moderators, with affiliations:*

Katri Hämeen-Anttila, PhD, Finnish Medicines Agency, Finland

Elin Høien Bergene, Hospital Pharmacist, Trondheim Hospital Pharmacy & PhD student, Norwegian University of Science and Technology

**Background:** Children use medicines widely and as medicine users, they should be provided information concerning their own medicines. However, depending on, e.g., age, development stage and experience of chronic illnesses and previous medicine use of an individual child, she or he may have to be approached differently. Furthermore, communicating with children is always different than communicating with adults. Thus, pharmacists need knowledge and skills to counsel their small patients.

**Aim:** The aim of this workshop is to learn how children of different ages can be counselled about medicines.

**Learning objectives:** During this workshop, the participants will
- get an understanding of how children’s thinking differ cognitively from adults’ thinking, acquire skills to communicate with children of different ages,
- identify challenges, and on the other hand, facilitating factors when communicating with children in different environments,
- gain practical tips for communicating with children

**Workshop program:** (total 120 min) Welcome and introduction (15 min)
- Introduction of the workshop leaders, the aims and program
- introduction of participants

**Mini-lectures (45 min):**
- Children as medicine users. Children’s cognitive development and how it impacts to communicating with children. Katri Hämeen-Anttila (25 min).
- How to increase child’s motivation for medicine taking. Elin Høien Bergene (20 min)

**Group work (30 min):** Workshop participants are divided in groups of 3–5 people. Each group choose the settings they want to focus, e.g., hospital unit or community pharmacy. In the groups the participants collectively
- identify barriers and challenges as well as facilitating factors when communicating with children in different environments
- discuss own experiences about best prac-
tics when communicating with children: what has worked and what has not worked.
• discuss available sources of medicine information for children. The groups are provided materials especially designed for children to facilitate their discussions

Discussion (30 min): Ideas and experiences shared in the group discussions will be shared and discussed with all participants focusing in two themes: discussing about the barriers and challenges in different environments and how they can be overcome, as well as facilitating factors identified sharing best practices and tips when communicating with children of different ages

WS07
Tackling inequalities in access to clinical pharmacist led healthcare: recognising and overcoming ethical issues of inclusion in research

Moderators with affiliation:
Dr Katie MacLure, PhD, MSc, BSc (Hons), Dip-SysPrac, PgCert, MBCS, SRPharmS, AFHEA, Senior Research Fellow & Lecturer, School of Pharmacy & Life Sciences, Robert Gordon University, Aberdeen, Scotland AB10 7GJ k.m.maclure@rgu.ac.uk
Ms Joan Macleod, MSc, MPharm, MRPharmS, Lead Pharmacist, NHS Grampian & Doctoral student, School of Pharmacy & Life Sciences, Robert Gordon University, Aberdeen, Scotland AB10 7GJ joan.macleod@nhs.net

Background: Clinical pharmacists are trained to treat people from all walks of life equally. Their work ethos and ethical practice promotes inclusion and respect for diversity. Pharmacy practice is evidence-based so it follows that research must also promote equality and inclusion while respecting diversity. All too often what are considered marginalised or vulnerable groups are excluded from participation in research because gaining the necessary ethical approvals is perceived to be overly challenging and methods of data collection often require adaptation. The paradox is that not researching such groups is in itself unethical.1-11

Aim: The aim of this workshop is to raise awareness of some of the ethical and practical issues in researching or not researching diverse populations. This workshop will challenge pharmacy practitioners to consider the inequalities inherent in research which undermine their evidence-base for tackling inequalities in their daily practice.

Learning Objectives: On completion of the workshop, the participants will be able to:
1- Recognise inequalities in research, asking why some groups are under-researched
2- Identify effective strategies to gain informed consent for marginalised or vulnerable group participation in research, asking what more we can do to tackle inequalities and promote inclusion
3- Reflect on the impact for evidence-based clinical practice, asking what we can do to tackle inequalities in access to clinical pharmacist-led healthcare

Content and Structure: The moderators will draw on their experience and expertise to encourage interaction and participation through small group based activities using a range of well-developed and tailored workshop materials.
- Introductions including an: Overview of the workshop and brief presentation on the ethical issues, inherent publication bias and perpetuation of the lack of evidence-base by not giving voice to marginalised and vulnerable groups
- Activities (facilitated in small groups) will focus on tackling inequalities in research involving elderly frail, people with learning disabilities, homeless people, refugees and children covering:
  - Research governance: how to gain ethical review
  - Recruitment: how to gain informed consent
  - Participation: how to facilitate and record engagement
Presentations and feedback:
- Each group presents their strategy for tackling inequalities through engagement, recruitment and participation of marginalised and vulnerable groups in research to inform clinical pharmacy practice

WS08
Guidelines for pharmaceutical care: nuisance or necessity?
Dr. Berry Daemen, Dr. Martina Teichert, Royal Dutch Pharmacists Association, The Hague, the Netherlands

Background: The primary goal of the Evidence Based Medicine (EBM) movement was to provide the best health care available to individual patients. To serve this goal the concept of clinical practice guidelines was developed. In a growing number of countries, pharmacists started with the development and the implementation of evidence based guidelines on pharmaceutical care. Aim: To share expectations on guidelines for pharmaceutical care, to discuss the necessity for guidelines on certain topics and to exchange experiences on how to be successful in the process of guideline development and implementation.

Learning Objectives: After this workshop participants should be able to:
1. Be aware of the pros and cons in guideline development;
2. Know arguments for developing guidelines for specific pharmaceutical care topics;
3. Name critical steps in the process of guideline development;
4. Be aware of barriers and have some ideas how to overcome them.

Content and Structure: Guideline development is complex. For a successful development and implementation of a clinical practice guideline all kinds of knowledge, skills and support are needed. In this process scientific knowledge and professional skills are combined with the support from healthcare professionals, patient organisations, health insurers and governmental policy. Organizations with experience in guideline development have defined a number of specific phases and steps in the development of guidelines. During this workshop, the participants will use these steps to plan the development of a guideline on a specific topic of pharmaceutical care. This workshop is above all interactive. The diversity en experiences of the participants will broaden the views on guidelines. In this workshop we will work in smaller groups where views on pharmaceutical care topics are exchanged. Experiences on the use of guidelines to implement and improve evidence based pharmaceutical care are discussed. Tips to take the subsequent steps of guideline development and to overcome barriers are collected. The insights from the group discussions are shared in plenum.

WS09 part 1
Moderated by members of the SIMPATHY consortium led by Alpana Mair Deputy Chief Pharmaceutical Officer, Pharmacy and Medicines Division, Directorate for Healthcare Quality and Strategy, Scottish Government

Background: Patients with multimorbidity are at risk of issues associated with polypharmacy and adherence to medicines. Management of care delivery to minimise these risks is challenging to healthcare professionals. It is known that there’s a wide variation in management of polypharmacy and adherence in the elderly across Europe ranging from national programmes of work to no specific management strategies. SIMPATHY, an EU funded project, is identifying and benchmarking strategies in place across European countries to address this issue. SIMPATHY aims to share best practice across EU countries through development and
implementation of tools and strategies to support multidisciplinary teams to ensure patients in Europe have access to appropriate management of polypharmacy.

**Aim:** The workshop aims to develop skills in clinical problem solving through case studies which illustrate the challenges of polypharmacy and adherence with medicines in elderly patients.

**Learning Objectives:** At the end of the workshop, participants will be able to

- Practise a systematic approach to clinical medication review to identify and propose solutions for medication related problems
- Make judgements about the appropriateness of prescribing taking into consideration potential benefits vs harm in the use of medicines
- Propose a plan to discuss potential medication changes with the prescriber and with the patient to solve patient problems and improve patient safety

**Content and Structure:** 30 participants over 2 hours

**Presentation:** 0-20 min: Introduction and plan for SIMPATHY workshops parts 1 and 2. Patient safety issues – facts and figures about harm from medicines. Brief overview of Polypharmacy Guidance, targeting patients for review and systematic approach to clinical medication review.

**Small Group Task (5 groups of 6):** 20-70 min: Groups to apply the systematic process to polypharmacy case studies. Use 2 case studies, allocate groups to focus on one and if time allows, consider the other. Provide copies of the systematic process. Groups to consider benefit vs harm and how they propose to approach communication with the prescriber and with the patient.

**Group Feedback:** 70-110 min: Groups feedback their proposed solutions (20 mins per case)

**Summary:** 110-120 min: Summarise and reflect on learning outcomes. Introduce part 2

---

**WS09 part 2**

**SIMPATHY Stimulating Innovation Management of Polypharmacy and Adherence in The Elderly (SIMPATHY) Part 2: Influencing change in practice**

*Moderated by members of the SIMPATHY consortium led by Alpana Mair (as above)*

**Background:** see part 1

**Aim:** The aim of this workshop is to share initial findings from the benchmarking exercise, introduce participants to change management tools in the context of the multidisciplinary approach to polypharmacy management and explore potential application of these tools.

**Learning Objectives:** At the end of the workshop, participants will be able to

- Describe the challenges in working collaboratively in multidisciplinary teams to deliver patient centred care to elderly patients taking multiple medicines to ensure appropriate polypharmacy.
- Consider the adoption of successful implementation strategies across EU countries to their own areas of practice
- Plan the application of change management principles to support engagement and adoption of SIMPATHY tools

**Content and Structure:** 30 participants over 2 hours

**Presentation:** 0-20 min: What is SIMPATHY trying to achieve (in terms of inequalities and access to care – theme of conference) including examples of programmes from different countries and challenges identified.

**Small Group Task (5 groups of 6):** 20-70 min: Drawing from the examples provided, ask groups to reflect on their own practices and try to benchmark where they are relative to the examples provided. Allow time for members of the group to share their own practice situation and reflect/discuss their position in the evolution of polypharmacy management. Handout 8 step process for implementing change (Kot-
WS10

Cultural Competence: Enhancing Pharmacist Communication for a Global Patient Population

First Moderator: Kyle Wilby, BSP, ACPR, PharmD, Assistant Professor & Coordinator of Assessment and Accreditation, College of Pharmacy, Qatar University, Doha, Qatar
Second Moderator: Kerry Wilbur, BScPharm, ACPR, PharmD, MScPH, FCSHP, Associate Professor, Director & Experiential Coordinator Doctor of Pharmacy College of Pharmacy, Qatar University, Doha, Qatar

Background: Pharmacists are increasingly placed in difficult situations requiring effective cross-cultural communication with patients and/or other health professionals (1, 2). As “culture” is a broad term generally defined as groups of people sharing similar values and beliefs systems, cross-cultural communication can relate to many different variables, including ethnicity, gender, language, sexual orientation, religion, and others. In fact, it is unknown when one might encounter a ‘cultural moment’ requiring self- and cultural-awareness of the situation at hand (3). Considering recent increases in migration of people (potential patients and health professionals) to Europe, North America, and elsewhere, it is more important than ever for pharmacists to be self-aware and exhibit cultural competence during care-related interactions (4, 5). In order to develop these skills, pharmacists must first be able to recognize actual and potential cultural conflicts, practice effective communication behaviours during interactions, and be open to self-reflection and evaluation for future personal and professional growth.

Aims: Using carefully selected examples of topics grounded in cultural sensitivity literature (narcotic use, antibiotics, herbal products, etc.), this workshop aims to provide participants with skills to recognize actual and potential cultural conflicts and strategies to promote self-awareness and reflection for personal and professional growth.

Learning Objectives:
- Recognize various situations where miscommunication and/or care conflicts may arise due to cultural differences (“cultural moments”);
- Consider one’s own initial responses in such circumstances and how these might affect the pharmacist’s relationship with patients or colleagues; and
- Outline and employ strategies to communicate in a culturally competent manner when given specific scenarios.

Workshop Content and Structure:
Welcome & Introduction by Moderators (10 minutes): Cultural competency in health: background and contemporary implications for pharmacists.
Task 1 by Small Groups (10 minutes): Participants will be asked to reflect upon what they believe to be prior experiences of “cultural moments” in care and consider their responses in these situations.
Facilitated Discussion by Moderators of Whole Group (15 minutes): Experiences will be shared across groups.
Task Orientation by Moderators (15 minutes):
Other examples shared to close discussion and introduce next small group task. Task 2 by Small Groups (30 minutes): Participants will conduct short role play/s and reflection given specific scenario/s (worksheets with prompts and small group discussion points to be provided).

Facilitated Discussion by Moderators of Whole Group (30 minutes): Small group representatives will be asked to share consensus on strategies explored and perceived most effective for culturally competent communication in their specific scenario.

Summary & Closing by Moderators (10 minutes).

WS11

How to convince the doctor
Moderators, with affiliations:
A.C.M. (Ankie) Hazen, MSc, PhD, pharmacist, Department of General Practice, UMC Utrecht, Julius center;
Dr. A.J. (Anne) Leendertse, clinical pharmacist, assistant professor, Department of General Practice, UMC Utrecht, Julius center.

Background: To have a positive impact on patient outcomes achieved with pharmacotherapy, it is likely that pharmacists will work more closely with physicians to collaboratively manage patients’ pharmacotherapy. However, only a proportion of pharmacotherapy recommendations made by pharmacists to physicians are implemented. (1) In general, poor pharmacist-physician communication leads to medication errors that can even result in death or permanent loss of function for a patient. (2) Therefore, there is a need to improve pharmacist-physician communication. From the Pharmacotherapy Optimization through Integration of a Non-dispensing Pharmacist in primary care Team (POINT) study (3) the pharmacists were given a tool to use in the communication with physicians and the documentation of drug therapy problems. The PIAPE tool focuses on the problem of the patient combined with clinical information, assessment, the treatment plan and evaluation (monitoring) of the problem. In this workshop we will analyze several clinical patient cases with the PIAPE tool to help the pharmacist in effective communication with a physician.

Aim: The aim of this workshop is to improve communication with the physician to improve patient outcomes and medication safety.

Learning Objectives:
1. After the workshop, participants should be able to identify drug therapy problems which are clinically relevant;
2. The participant learn about a tool to document drug therapy problems from a patient and physician perspective;
3. The participant learn about a tool to improve communicate about drug therapy problems and implementation of recommendations with the physician.

Content and Structure:
- short presentation about the PIAPE tool with handout,
- applying of the tool to several patient cases in writing,
- discussing the cases in small groups,
- plenary discussion and feedback on the cases.

WS12

Controversy and consensus of integrating a clinical pharmacist into practice
Moderators, with affiliations:
A.C.M. (Ankie) Hazen, MSc, PhD, pharmacist, Department of General Practice, UMC Utrecht, Julius center. Dr. A.J. (Anne) Leendertse, clinical pharmacist, assistant professor, Department of General Practice, UMC Utrecht, Julius center.

Background: Co-locating a non-dispensing clinical pharmacist (NDP) in primary care practice is expected to improve interprofessional collaboration and communication and thus pharmaceutical care. However, the controversy about this new role for pharmacists hampers broad implementation. In the Netherlands, a study was set up to
systematically map the debate amongst all involved stakeholders (e.g., general practitioners and pharmacists) on the introduction of NPDs in primary care practice. In this workshop we will identify and learn about controversy and consensus. From four different perspectives (“the independent community pharmacist”, “the independent clinical pharmacist”, “the dependent clinical pharmacist” and “the clinical managed-care pharmacist”) provoking statements will be discussed. Insights in these perspectives will be of use for successful implementation of the clinical pharmacist in your own practice.

**Aim:** The aim of this workshop is to learn about the implementation of a clinical pharmacist in order to improve pharmaceutical care.

**Learning Objectives:**
1. After the workshop, participants should be able to identify and learn about different perspectives on integrating a clinical pharmacist into practice;
2. The participant learn about consensus and controversy of integrating a clinical pharmacist into practice;
3. The participants develop ideas about improving interprofessional collaboration within their own healthcare setting.

**Content and Structure:**
- Short presentation about the four perspectives (“the independent community pharmacist”, “the independent clinical pharmacist”, “the dependent clinical pharmacist” and “the clinical managed-care pharmacist”);
- Interactive game with provoking statements;
- Group discussion and evaluation.

**WS13**

Skills set development for Advanced Clinical Pharmacy Practitioners

**Moderators with affiliations:**
Professor Rosemarie Parr, Chief Pharmaceutical Officer, Scottish Government Health Department & Fiona Reid, Principal Lead Pharmacist (Prescribing & Clinical Skills) NHS Education for Scotland

**Background:** Traditional healthcare delivery is constrained secondary to reduced resources, medical, nursing and financial, and increased requirements secondary to an aging population with multimorbidities. As a result policy has shifted to maximise delivery of patient care utilising clinical skills of the multidisciplinary team working (1). Recent developments in the United Kingdom advocate the development of Clinical Pharmacists working in General Practice settings (2, 3) and in NHS Scotland the Vision and Action Plan, A Prescription for Excellence advocates that all patient facing pharmacists will be Accredited Clinical Pharmacist Independent Prescribers (4).

**Aim:** The aim of this workshop is to provide clinical pharmacy practitioners with the ability to review and plan the skills set required for those working in Advanced Clinical Practitioner roles. Detail in relation to identification of training needs, skills set development and ongoing support requirements to implement safe and effective clinical practice will be explored.

**Learning Objectives:** On completion of the workshop participants will be able to:
1. Describe methods to identify systematically the training needs for this group of practitioners
2. Identify methods to support planning and delivery of the required skills set
3. Explain potential systems for ongoing assessment of safe and effective practice
4. Reflect upon pathways for clinical skills developments at individual and team levels

**Content and Structure:** The moderators will draw on their experience both within Education and Training and Clinical Practice to encourage interaction and participation through facilitated small group activities. A short presentation will
conclude the session highlighting the ways in which Advanced Practice has been developed and supported to date within Scotland.

**WS14**

**What can a clinical pharmacist do to reduce medication waste?**

*Moderator(s), with affiliations:*
- Charlotte L Bekker, MSc, PhD student, Department of Pharmacy, Sint Maartenskliniek, Department of Clinical Pharmacy, Utrecht University Medical Centre, The Netherlands,
- Dr. Lorna M West, B.Pharm (Hons), MSc, PhD, Post-doctoral researcher and Visiting Assistant Lecturer, Department of Pharmacology and Therapeutics, University of Malta, Malta,
- Marcel L Bouvy, Professor of Pharmaceutical Care, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands

**Background:** The yearly disposal of tons of unused medication has a resultant burden on the health care budget, as well as environmental implications in relation to disposal. By virtue of the multidisciplinary role within an organization and their close contact with the patient, clinical pharmacists can play an important role in decreasing medication waste. Exploring new and existing interventions to decrease medication waste will further empower the clinical pharmacist to reduce medication waste, subsequently benefitting the complete health care system.

**Aim:** To explore existing and new strategies within the clinical pharmacy community to reduce medication waste and to translate these into participant’s own clinical practice.

**Learning Objectives:** After the workshop, participants will be able to:
1. Describe practical strategies to decrease medication waste in the prescribing phase, the dispensing phase, during patient use and (possibly) by redispensing of unused medication
2. Target those strategies on three stakeholders: health care organizations, health care professionals and patients
3. Describe potential barriers and facilitators of each strategy
4. Take a statement on the redispensing of unused medicines: pro’s and con’s
5. Reflect on approaches to reduce waste within their own clinical practice

**Content and Structure:**

- **Introduction** – Key findings of the literature on medication waste will be highlighted. These include often absent and inconsistent definition of ‘medication waste’, lack of valid, reliable outcome measures and dearth of literature on implementation of interventions to reduce waste.
- **Workshop** – The majority of the time will comprise interactive group work (4-5 participants) during which each subgroup will be assigned to several case studies. The case studies will be explored in depth with the following activities:
  1. Exploring existing and new strategies to reduce medication waste during different aspects of the pharmaceutical supply chain: the prescribing process, the dispensing process, patient use and the redispensing process.
  2. Describing the roles that different stakeholders can fulfil in each strategy, by considering what they perceive as medication waste with the focus on:
     - Participant’s local and national strategies to decrease medication waste (organization level)
     - How clinical pharmacists can specifically decrease medication waste (professional level)
     - How patients can be involved in decreasing medication waste (patient level)
  3. Assessing the barriers and facilitators that are related to those strategies.
- **Group discussion** – An individual from each group will present their subgroup findings.
of the case studies. At the end of the workshop, participants will be asked to reflect on the possibility of implementing the discussed key solutions to reduce medication waste in their individual clinical practice.

**WS15**

**Motivational interviewing: A useful method for clinical pharmacists to change patients’ health behavior**

*Moderators with affiliation:*

_Ulla Hedegaard, MScPharm, PhD, Associate Professor, Odense University Hospital & Clinical Pharmacology and Pharmacy, University of Southern Denmark.*

_Christina Skovsende Eriksen, MScPharm, Psychiatric Centre Glostrup, Capital Region of Denmark._

**Background:** Negative medication- and lifestyle behaviour is associated with poor health outcomes, and clinical pharmacists have an important role in helping patients to improve behaviour. Conventional patient counselling, where the pharmacist provides information to the patient, is not very effective in changing behaviour, and therefore more patient-centered methods which focus on patient autonomy, collaboration and patient empowerment have been developed. One new approach is motivational interviewing (MI) which originally was developed in the context of addiction treatment, but with growing evidence for change of behaviour related to lifestyle and medication adherence. MI is client-centered and intends to initiate change by creating dissonance between a patient’s current status and the target behaviour without making the patient feel threatened or pressured. MI is designed to help patients discover their own resources and solution. Pharmacists are traditionally taught that they are experts and in charge, and training is therefore needed to adapt to a more client-centered approach such as MI.

**Aim:** This workshop will bring together pharmacists with an interest in communication skills and intervention to improve medication- and lifestyle behaviour. Participants should achieve knowledge of MI and be introduced to use of simple techniques of MI.

**Learning objectives:** After the workshop, participants will be able to:

- Explain the “spirit” and key principles of motivational interviewing
- Differentiate between good and poor performance in motivational interviewing
- Recognise statements from the patient that indicate motivation for change (“change talk”)
- Recognise when good practice principles for motivational interviewing are not followed
- Use some simple techniques of motivational interviewing

**Content and structure:**

- Introduction to key principles and the “spirit” of MI (15 min)
- Use motivational interview video clips to demonstrate key principles of motivational interviewing – how to do it and how not to do it. (15 min)
- 5 min. introductions to specific techniques, e.g. open-ended questions, reflective listening, affirmation, responding to resistance and summarizing. (3x5 min)
- Exercise about simple and complex reflections undertaken in subgroups followed by group discussion (15 min)
- Role play – participants have the opportunity to role play being the interviewer and the patient and also have the opportunity to observe other role play scenarios and provide feedback. (2x15 min)
- Feedback, summary and reflection on learning outcomes. (15 min)

(total 105 min) + 15 min for change between sessions.
WS16
The role of the clinical pharmacist in an acute pain management team, contemporary approach to acute post-operative pain

Moderators, with affiliations:
Jana Lass MSc Clin Pharm, PhD, Tartu University Hospital, Estonia; Anne-Grete Märtson, MSc Pharm, Tartu University Hospital, Estonia

Background: Appropriate acute pain management is the cornerstone of patient care. If acute postoperative pain is not controlled then this will lead to longer hospital stay and in the long run may lead to development of chronic pain. A multi-professional pain management team will help prevent and reduce these problems.

Aim: The aim of this workshop is to describe the assessment, management and benefits of early treatment of acute pain. Also to develop a discussion about the role of the clinical pharmacist in the pain management team and possible new strategies of treating pain.

Learning Objectives:
- Learn about the structure and work of a multi-professional pain management team and the role of the clinical pharmacist within the team
- Learn about the contemporary approach to managing acute post-operative pain
- Learn about same experience in other countries via discussion

Content and Structure:
Introduction: Brief introduction to the topic and description of the everyday work of Tartu University Hospital pain management team.
Main topics:
- Clinical pharmacist role in the pain management team
- Patient specific aspects of analgesic use
- Comparison of different practices
- Case discussion

WS17
How can we optimize clinical pharmacy efficiency with a limited budget?

Moderators, with affiliations:
Barbara Claus, Hospital Pharmacist, Ghent University Hospital & Professor at Ghent University, Faculty of Pharmaceutical Sciences De Pintelaan 185, 9000 Ghent, Belgium
Yolande Hanssens, SIG Leader Medicine Information, PO Box 11717, Doha, Qatar

Background: A lot of European pharmacists face limited budgets to perform their clinical pharmacy activities. In most cases the turn-over of patients is much higher than the available resources. This workshop will support attendees in improving their ability to pinpoint patients with the highest need of pharmacy consultation and follow-up.

Aims of the workshop:
- to provide literature references and strategies to identify high-risk patients
- to highlight the importance as well as the pitfalls of focusing on high-cost drugs
- to make the link with cost-effectiveness of therapy outcomes
- to consider ethical aspects to minimize inequalities of clinical pharmacy services

Learning Objectives (min 2, max 4):
- To enable the participants
- To critically review and restructure clinical pharmacy activities in the own work setting (regardless of the position in the hospital: junior, senior pharmacist, manager, daily practitioner or ‘start-up’ pharmacist)
- To be aware of the ethical considerations when making choices
- To identify high risk patients and the value of electronic decision rules to maximize clinical pharmacy output
- To think in a basic pharmaco-economic way and adopt the principle: “if the effort is not in balance with the output, then a re-evaluation is needed”

Content & Structure: The content is brought to the audience by means of interactive exercises (interactive audience voting system (Turning point if possible) and other mind games.
- Introduction: providing standard definitions and related terminology of ethics and pharmacoeconomics 10 min
- Critical evaluation of a basic framework to define high-risk patients (both plenary and in small groups) (Part 1). 30 min
- Feedback part 1: the different elements of the small group discussions will be brought together in a plenary overview with a summary of some final statements 20 min
- Part 2: case presentations to apply theory. Some of these cases will challenge the participants to think in an economic way. Upon completion of these exercises, the aspect of high-cost drugs will be discussed. 30 min
- Summary of the information presented and take home messages 10 min

WS18
Administration of Vaccines and Injectable Drugs by Pharmacists: Frameworks, Impact and Challenges
Moderator: Mara Guerreiro, PharmD, PhD PgDip, Invited Associate Professor (ISCSEM) & Consultant (4Choice Health Consultancy), Portugal, mara.guerreiro@sapo.pt

Background: Vaccine-preventable diseases in Europe are still associated with morbidity, disability and mortality. (1) Access and convenience remain key issues for improving vaccination rates. Several countries have regulations which allow pharmacists to administer vaccines and, in some cases, other injectable drugs. (2) Internationally the framework under which this service is provided varies; differences include eligible drugs/vaccines and the nature of remuneration (public/private/out-of-pocket). There is a growing body of literature on the evaluation of pharmacy-based injection provision, focusing on measures such as vaccination rates, clients’ preferences and cost.

Aim: The aim of this workshop is to review existing frameworks for administration of vaccines and injectable drugs in community pharmacies, its impact and challenges concerning implementation.

Learning Objectives: By the end of the workshop participants should be able to:
- List countries which allow pharmacists to administer injections;
- Discuss key aspects of international frameworks for this practice;
- Discuss the impact of pharmacy-based injection provision;
- Discuss challenges related to implementation and possible strategies to address these challenges.

Content and Structure: After an “ice-breaker” activity the workshop will give an overview of countries where pharmacists are allowed to administer injections and of international frameworks for this practice. Secondly, the impact of pharmacy-based injection provision will be briefly presented. Participants will then be split in groups to discuss specific challenges in implementation of this service and possible ways to address them. The workshop will be reconvened and the contributions of each group will be debated. Closure will consist of a wrap-up session.

WS19
Less is more? Deprescribing in older polypharmacy patients
Moderators, with affiliation:
Katja Taxis, University of Groningen, the Netherlands
Anne Gerd Granas, Oslo and Akershus University College, Norway

Background: Over the last decades, there has been a major increase in drug use in older people [1]. Drug treatment is essential in both treatment and prevention of diseases, but late in life, the focus should be on symptomatic treatment to increase patient’s well-being. Consequently, the number of medicines should decrease and non-pharmacological alternatives should be used whenever possible. This process
can be called deprescribing, recently defined as “the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy and improving outcomes” [2].

**Aim:** Upon completion of this workshop participants will know the basic concepts of deprescribing and will be able to apply this in practical patient cases.

**Learning objectives:**
- Participants will be able to define the process of deprescribing.
- Participants will gain knowledge of a number of tools used during the deprescribing process.
- Participants will know a number of barriers and facilitators of deprescribing in different settings (e.g. community pharmacy and nursing homes).
- Participants will be able to apply deprescribing in simple/complex patient cases (depending on prior knowledge).

**Content:** In this workshop we will give a short introduction to the concept of deprescribing. The main part of the workshop will consist of discussing real clinical cases of (very) old polypharmacy patients in small groups. Participants are asked to outline a plan on how to optimize the patient’s pharmacotherapy considering advantages, disadvantages and practical issues of deprescribing as well as discuss potential underuse of beneficial medication. The final part of the workshop will be used to discuss the main outcomes from the patient cases and to share some practical experiences with deprescribing in the different countries and settings.

**Structure including a time schedule:**
- Welcome and introduction: 25 min
- Outline of group work: 5 min
- Discussion of patient cases in small groups (5-8 participants): 60 min
- Feedback about group work and summary of patient cases: 20 min
- Summary and wrap up: 10 min